Strides Pharma Science Ltd

Strides Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Strides Pharma Science Ltd

₹ 619 0.67%
15 Apr - close price
strides.com BSE: 532531 NSE: STAR
About

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]

Key Points

Business Segments
1) Pharma Generics: Its generic pharma business is driven by IP-based product licensing and global marketing and distribution partnerships. It specializes in manufacturing niche generic formulations in various dosage forms, like tablets, capsules, liquids, and sachets, focusing on regulated markets including the United States, Europe, Australia, etc. It has emerged as one of the world’s leading producers of soft gelatin capsules. [1] [2]

Website BSE NSE
  • Market Cap ₹ 5,710 Cr.
  • Current Price ₹ 619
  • High / Low ₹ 786 / 322
  • Stock P/E 22.9
  • Book Value ₹ 246
  • Dividend Yield 0.40 %
  • ROCE 7.85 %
  • ROE 4.48 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 2.51 times its book value
  • Promoter holding is low: 26.8%
  • Company has a low return on equity of -4.67% over last 3 years.
  • Promoters have pledged 54.2% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare BSE Allcap Nifty Microcap 250 Nifty Total Market BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
794 866 940 897 865 986 930 999 1,006 1,084 1,088 1,167 1,154
817 868 936 844 892 871 796 889 876 903 882 983 943
Operating Profit -23 -1 4 53 -27 115 134 111 129 181 205 184 210
OPM % -3% -0% 0% 6% -3% 12% 14% 11% 13% 17% 19% 16% 18%
-5 9 -52 57 68 20 3 -129 60 -22 9 25 4
Interest 42 49 55 68 58 81 76 79 70 80 80 74 52
Depreciation 61 61 60 62 60 61 60 60 49 50 49 48 48
Profit before tax -131 -103 -163 -20 -78 -7 0 -157 70 30 85 86 114
Tax % -3% -128% -17% -197% 5% 106% 3,025% -5% 23% 65% 20% 16% 21%
-127 29 -135 19 -82 -14 -9 -149 54 10 68 72 90
EPS in Rs -13.55 3.25 -15.13 2.53 -8.86 -1.06 -0.79 -14.54 5.40 1.98 7.64 7.81 9.54
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Dec 2012 Mar 2014 15m Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
962 1,341 1,196 2,861 2,755 2,845 2,178 2,752 3,316 3,070 3,688 4,051 4,492
861 1,567 967 2,486 2,228 2,448 1,982 2,351 2,779 3,201 3,544 3,484 3,712
Operating Profit 101 -226 229 374 527 398 197 401 537 -131 145 568 781
OPM % 10% -17% 19% 13% 19% 14% 9% 15% 16% -4% 4% 14% 17%
959 3,281 874 63 291 643 303 -30 109 -112 92 -95 16
Interest 79 109 47 168 183 196 79 156 150 177 261 314 287
Depreciation 31 56 64 131 126 154 117 174 206 233 243 221 195
Profit before tax 949 2,890 992 137 509 690 303 42 289 -653 -268 -63 315
Tax % 11% 39% 15% 31% 12% 1% -9% 27% 11% -27% -21% 50%
847 1,767 844 95 446 684 330 31 258 -474 -212 -94 241
EPS in Rs 143.92 296.43 141.78 12.15 44.71 74.25 36.27 4.06 29.93 -51.25 -22.44 -7.68 26.97
Dividend Payout % 1% 170% 76% 41% 10% 3% 8% 345% 8% 0% -7% -33%
Compounded Sales Growth
10 Years: 12%
5 Years: 13%
3 Years: 7%
TTM: 15%
Compounded Profit Growth
10 Years: -25%
5 Years: -20%
3 Years: -23%
TTM: 2306%
Stock Price CAGR
10 Years: 2%
5 Years: 31%
3 Years: 54%
1 Year: 59%
Return on Equity
10 Years: 10%
5 Years: 0%
3 Years: -5%
Last Year: 4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 59 60 60 89 89 90 90 90 90 90 90 92 92
Reserves 1,967 947 1,085 2,569 2,659 2,374 2,559 2,438 2,687 2,269 2,122 2,034 2,179
1,594 547 892 3,542 3,700 2,520 3,221 2,235 2,348 3,025 3,030 2,517 2,308
1,175 543 438 1,211 1,598 1,601 1,937 1,369 1,844 1,556 1,352 1,157 1,410
Total Liabilities 4,796 2,096 2,475 7,410 8,046 6,585 7,807 6,131 6,969 6,940 6,594 5,799 5,990
3,017 555 701 2,679 2,980 2,977 3,648 2,099 2,219 2,347 2,311 1,865 1,987
CWIP 241 99 171 815 780 620 453 413 447 291 151 162 154
Investments 0 443 630 1,341 1,525 588 702 549 697 540 490 303 243
1,538 999 972 2,576 2,762 2,400 3,005 3,070 3,605 3,762 3,642 3,470 3,605
Total Assets 4,796 2,096 2,475 7,410 8,046 6,585 7,807 6,131 6,969 6,940 6,594 5,799 5,990

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
139 -272 83 73 288 187 60 205 481 -258 44 701
771 4,044 50 -2,205 -1,222 570 -145 1,321 -522 -119 302 -150
-990 -3,319 -421 2,944 338 -1,016 194 -1,709 -16 421 -214 -693
Net Cash Flow -80 454 -288 812 -596 -259 110 -184 -56 45 133 -142

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 183 99 119 132 132 113 165 124 122 144 129 103
Inventory Days 328 90 135 149 209 146 294 254 329 285 257 251
Days Payable 344 137 153 188 221 188 299 259 311 260 220 189
Cash Conversion Cycle 168 52 102 92 120 71 160 119 140 168 165 164
Working Capital Days 18 53 -29 96 63 117 155 95 116 210 156 141
ROCE % 27% 113% 57% 8% 11% 16% 6% 5% 8% -5% -0% 8%

Shareholding Pattern

Numbers in percentages

1 Recently
Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
30.60% 30.37% 31.08% 30.90% 28.28% 28.08% 27.79% 27.39% 25.88% 25.86% 25.84% 26.82%
19.66% 21.21% 21.43% 18.98% 18.85% 16.72% 17.25% 19.45% 24.57% 26.71% 30.08% 28.48%
18.82% 16.63% 15.07% 18.44% 17.88% 19.60% 19.50% 19.02% 17.66% 18.17% 18.24% 16.92%
0.00% 0.00% 0.40% 0.40% 0.40% 0.40% 0.40% 0.39% 0.39% 0.39% 0.01% 0.01%
30.92% 31.79% 32.05% 31.29% 34.60% 35.22% 35.06% 33.75% 31.52% 28.87% 25.83% 27.78%
No. of Shareholders 1,33,1901,34,7181,30,6821,23,9641,20,9161,12,7751,01,63891,18284,69591,91796,0091,14,237

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls